New combo therapy aims to shrink rectal tumors and avoid surgery
NCT ID NCT07291401
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests whether adding an immunotherapy drug (QL1706) to standard chemoradiation can help shrink advanced rectal cancer more effectively. About 108 adults with stage 2 or 3 rectal cancer will be randomly assigned to receive either the standard treatment or the standard treatment plus immunotherapy. The goal is to see if the new combination leads to a complete disappearance of the cancer, potentially allowing some patients to avoid surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.